Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




FDA Takes Action to Stop Marketing of Unapproved Colchicine Injection
Link ID 3050
Title FDA Takes Action to Stop Marketing of Unapproved Colchicine Injection
Url http://www.medscape.com/viewarticle/569866?src=rss
Description The US Food and Drug Administration has received 50 reports of adverse events with colchicine injection, including 23 deaths, related to product use. Medscape Medical News
Category Articles > Business of Medicine
Keywords
Date Feb 8, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. Bayer Yanks Aprotinin off the Market Pending Analysis of BART
  The company says the marketing suspension is "temporary" pending a full analysis of the trial, which pointed to higher rates of 30-day mortality among high-risk surgery patients randomized to aprotinin. Medscape Medical News
Category:   Articles > Business of Medicine


2. Patients, Caregivers, and the Danger of Imaging Studies: The Four Horsemen of the Radiology Apocalyp
  The subject of radiation-induced cancer from CT is controversial, and is disputed, primarily by radiologists, citing lack of scientific evidence.
Medscape Radiology
Category:   Articles > Business of Medicine


3. Medtronic Gets FDA Nod for Blood Sugar Monitoring Device
  Medtronic Inc said U.S. health regulators approved its blood sugar monitoring device, the CGMS iPro Recorder. Reuters Health Information
Category:   Articles > Business of Medicine


4. FDA Reprimands GlaxoSmithKline Over Missing Data on Rosiglitazone
  In a letter to GlaxoSmithKline, the FDA said that an inspection in late 2007 focusing on compliance with postmarketing adverse drug experience reporting requirements found that the company failed to report data from clinical usage and failed to disclose or submit data from clinical trials. Heartwire
Category:   Articles > Business of Medicine


5. Antiviral Drug Labels Get Warnings for Neuropsychiatric Changes
  Patients with influenza should be closely monitored for signs of abnormal behavior during treatment with Tamiflu and possibly also Relenza. Medscape Medical News
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS